OBJECTIVES AND METHODS: The purpose of this study was to examine the incidence of mild cognitive impairment (MCI) and patterns of progression from incident MCI to dementia in 285 cognitively normal subjects (mean age, 78.9 years) in the Cardiovascular Health Study-Cognition Study from 1998-1999 to 2010-2011. RESULTS: Two hundred (70%) of the participants progressed to MCI; the age-adjusted incidence of MCI was 111.09 (95% confidence interval, 88.13-142.95) per 1,000 person-years. A total of 107 (53.5%) of the incident MCI subjects progressed to dementia. The mean time from MCI to dementia was 2.8 ± 1.8 years. Forty (20%) of the incident MCI cases had an "unstable" course: 19 (9.5%) converted to MCI and later returned to normal; 10 (5%) converted to MCI, to normal, and later back to MCI; 7 (3.5%) converted to MCI, to normal, to MCI, and later to dementia; and 4 (2%) converted to MCI, to normal, and later to dementia. There was an increased mortality rate among the cognitively normal group (110.10 per 1,000 person-years) compared to those with incident MCI who converted to dementia (41.32 per 1,000 person-years). CONCLUSIONS: The majority of the subjects aged >80 years developed an MCI syndrome, and half of them progressed to dementia. Once the MCI syndrome was present, the symptoms of dementia appeared within 2 to 3 years. Progression from normal to MCI or from normal to MCI to dementia is not always linear; subjects who developed MCI and later returned to normal can subsequently progress to dementia. Competing mortality and morbidity influence the study of incident MCI and dementia in population cohorts.
OBJECTIVES AND METHODS: The purpose of this study was to examine the incidence of mild cognitive impairment (MCI) and patterns of progression from incident MCI to dementia in 285 cognitively normal subjects (mean age, 78.9 years) in the Cardiovascular Health Study-Cognition Study from 1998-1999 to 2010-2011. RESULTS: Two hundred (70%) of the participants progressed to MCI; the age-adjusted incidence of MCI was 111.09 (95% confidence interval, 88.13-142.95) per 1,000 person-years. A total of 107 (53.5%) of the incident MCI subjects progressed to dementia. The mean time from MCI to dementia was 2.8 ± 1.8 years. Forty (20%) of the incident MCI cases had an "unstable" course: 19 (9.5%) converted to MCI and later returned to normal; 10 (5%) converted to MCI, to normal, and later back to MCI; 7 (3.5%) converted to MCI, to normal, to MCI, and later to dementia; and 4 (2%) converted to MCI, to normal, and later to dementia. There was an increased mortality rate among the cognitively normal group (110.10 per 1,000 person-years) compared to those with incident MCI who converted to dementia (41.32 per 1,000 person-years). CONCLUSIONS: The majority of the subjects aged >80 years developed an MCI syndrome, and half of them progressed to dementia. Once the MCI syndrome was present, the symptoms of dementia appeared within 2 to 3 years. Progression from normal to MCI or from normal to MCI to dementia is not always linear; subjects who developed MCI and later returned to normal can subsequently progress to dementia. Competing mortality and morbidity influence the study of incident MCI and dementia in population cohorts.
Authors: L P Fried; R A Kronmal; A B Newman; D E Bild; M B Mittelmark; J F Polak; J A Robbins; J M Gardin Journal: JAMA Date: 1998-02-25 Impact factor: 56.272
Authors: Oscar L Lopez; Lewis H Kuller; James T Becker; Corinne Dulberg; Robert A Sweet; H Michael Gach; Steven T Dekosky Journal: Arch Neurol Date: 2007-03
Authors: V Solfrizzi; F Panza; A M Colacicco; A D'Introno; C Capurso; F Torres; F Grigoletto; S Maggi; A Del Parigi; E M Reiman; R J Caselli; E Scafato; G Farchi; A Capurso Journal: Neurology Date: 2004-11-23 Impact factor: 9.910
Authors: Lubov E Zeifman; William F Eddy; Oscar L Lopez; Lewis H Kuller; Cyrus Raji; Paul M Thompson; James T Becker Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: I Contador; F Bermejo-Pareja; A J Mitchell; R Trincado; A Villarejo; Á Sánchez-Ferro; J Benito-León Journal: Eur J Neurol Date: 2013-10-15 Impact factor: 6.089
Authors: Petra Bůžková; Joshua I Barzilay; Howard A Fink; John A Robbins; Jane A Cauley; Annette L Fitzpatrick Journal: J Clin Endocrinol Metab Date: 2014-08-22 Impact factor: 5.958
Authors: Rosebud O Roberts; David S Knopman; Michelle M Mielke; Ruth H Cha; V Shane Pankratz; Teresa J H Christianson; Yonas E Geda; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Walter A Rocca; Ronald C Petersen Journal: Neurology Date: 2013-12-18 Impact factor: 9.910
Authors: Mary M Machulda; V Shane Pankratz; Teresa J Christianson; Robert J Ivnik; Michelle M Mielke; Rosebud O Roberts; David S Knopman; Bradley F Boeve; Ronald C Petersen Journal: Clin Neuropsychol Date: 2013-09-17 Impact factor: 3.535